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Abstract
Rationale The P3 is a ubiquitous component of stimulus-
driven neural activity that can be observed in scalp electro-
physiological recordings. Multiple lines of evidence suggest
an important role for the noradrenergic system in the genera-
tion of the P3. However, pharmacological studies of the P3
using noradrenergic manipulations have so far been limited to
agents that affect α2-receptor signaling.
Objectives The present study investigated whether β-
adrenergic receptors are involved in the generation of the P3
and the error positivity (Pe), a component of the event-related
potential that is elicited by errors and that bears many similar-
ities to the P3.
Methods We used a double-blind, placebo-controlled, cross-
over design in which we examined in human participants (N=
16) the effect of a single dose of propranolol (80 mg) on the
amplitudes of the P3 observed in visual and auditory oddball
tasks and the Pe observed in a flanker task.
Results We found that P3s to auditory stimuli were increased
in amplitude following treatment with propranolol. Proprano-
lol also modulated the P3 to visual stimuli, but in a direction
dependent on participants’ level of trait anxiety: In
participants with lower trait anxiety, propranolol resulted in
a (non-significant) decrease in P3 amplitudes; in participants
with higher trait anxiety, propranolol significantly enhanced
P3 amplitude. Propranolol did not modulate the amplitude of
the Pe or behavioral measures of conflict/error-related perfor-
mance adjustments.
Conclusions These results provide the first evidence for in-
volvement of β-adrenergic receptors in P3 generation. We
speculate that propranolol affected the P3 through actions at
β2-receptors in the locus coeruleus.
Keywords Beta-blockers . Norepinephrine . P300 . ERP .
EEG . Error processing . Post-error slowing . Conflict
adaptation . Antagonist . InvertedU
Introduction
The P3 (or P300) is a ubiquitous component of stimulus-
driven neural activity that can be observed in electroencepha-
lography (EEG) recordings. Researchers generally agree that
the P3 must reflect key aspects of information processing,
such as updating of memory (Donchin and Coles 1988; see
also Nieuwenhuis 2011), decision making (O’Connell et al.
2012; Verleger et al. 2005), and temporal filtering
(Nieuwenhuis et al. 2005). To understand the neurochemical
mechanisms underlying generation of the P3, a large number
of studies have examined the effects on the P3 of pharmaco-
logical manipulations that affect one or several neurotransmit-
ter or neuromodulator systems. These studies have implicated
a variety of neurochemical systems in P3 generation (Frodl-
Bauch et al. 1999; Polich 2007; Soltani and Knight 2000), but
the most consistent P3 effects have probably been obtained in
pharmacological studies of the noradrenergic system. This
system consists of the brainstem nucleus locus coeruleus
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(LC) and widespread ascending projections throughout the
brain, where LC activity leads to the release of the
neuromodulator norepinephrine (noradrenaline) (Berridge
and Waterhouse 2003). There is a wealth of evidence that
the P3 reflects, at least in part, the neuromodulatory effect of
phasic norepinephrine release in the neocortex (de Taeye et al.
2014; Nieuwenhuis 2011; Nieuwenhuis et al. 2005). The pri-
mary goal of the current study was to examine in more detail
the role of the noradrenergic system in generation of the P3.
The second goal was to test for noradrenergic modulation of
the error positivity (Pe), a broad positive event-related poten-
tial (ERP) component elicited by errors that shows many sim-
ilarities to the P3.
Noradrenergic signaling occurs through three major cate-
gories of receptors: α1, α2, and β, each type being associated
with different cellular responses (Berridge and Waterhouse
2003) and cognitive functions (Chamberlain and Robbins
2013). Therefore, it is surprising that P3 studies using norad-
renergic manipulations have been limited to agents that affect
α2-receptor signaling—mostly clonidine, an α2-receptor ag-
onist that at moderate doses decreases noradrenergic activity.
Although the results are not unequivocal (e.g., Shelley et al.
1997), the large majority of these studies has found that clo-
nidine decreases P3 amplitude, especially in auditory target
detection tasks (Logemann et al. 2013; Turetsky and Fein
2002; other studies are reviewed in Nieuwenhuis et al. 2005).
So far, there have been no published studies that examined
the role of β-receptor signaling in P3 generation. This is sur-
prising given the strong relationship between P3 amplitude
and learning (Donchin and Coles 1988; see also
Nieuwenhuis 2011) and the fact that norepinephrine promotes
long-term potentiation, a prominent neural substrate for learn-
ing and memory, through actions at β-adrenergic receptors
(Gibbs and Summers 2002). Strange and Dolan (2007) found
that propranolol, a centrally acting β-receptor antagonist,
abolished the large blood–oxygen level-dependent (BOLD)
response elicited by oddball targets in areas that receive strong
noradrenergic projections and that contribute significantly to
the scalp-recorded P3. This suggests that propranolol should
decrease oddball P3 amplitude. Testing this hypothesis was
the primary aim of our study.
Several authors have noted the similarities between the P3
and the Pe (Leuthold and Sommer 1999; Overbeek et al. 2005;
but see Falkenstein et al. 2000), a positive component that
typically peaks between 200 and 400 ms after incorrect re-
sponses, immediately following the error-related negativity
(ERN). The P3 and Pe have a similar polarity, morphology,
and timing, and both components are elicited by motivationally
significant events, which has led to the proposal that the Pemay
constitute a P3 associated with the motivational significance of
an error (Overbeek et al. 2005; Rösler 1983). Recent principal
component analyses of the Pe have shown that it consists of two
subcomponents, a fronto-central component with a similar
spatial distribution as the error-related negativity and a centro-
parietal component closely resembling the P3 (Arbel and
Donchin 2009; Endrass et al. 2012). Intracranial recordings in
humans suggest that the Pe, like the P3 (Nieuwenhuis et al.
2005), has widely distributed cortical sources (Brázdil et al.
2002; see also Helenius et al. 2010). Furthermore, two studies
have reported a significant positive across-subject correlation
between the amplitude of the Pe and the amplitude of the P3
recorded in the same task (Davies et al. 2001) or a different task
(Ridderinkhof et al. 2009). Finally, the two components have
both been argued to reflect a decision variable that integrates
noisy evidence until it reaches a boundary-crossing criterion:
While the P3 may reflect the accumulation of evidence that a
target stimulus has occurred (Nieuwenhuis 2011; O’Connell
et al. 2012), the Pe may reflect accumulated evidence that an
error has been committed (Murphy et al. 2012; Steinhauser and
Yeung 2010).
These results, indicatingmany parallels between the P3 and
Pe, suggest that pharmacological agents that affect the P3 may
also affect the Pe. The secondary aim of our study was to test
this prediction. We examined the effects of a single dose of
propranolol (80 mg) on P3 and Pe amplitude using a double-
blind, placebo-controlled crossover design. P3s were elicited
using visual and auditory oddball tasks; Pes were elicited by
errors in a flanker task. Because of the inverted U-shaped
relationship between baseline noradrenergic activity and pha-
sic noradrenergic responses (Aston-Jones and Cohen 2005),
the effects of noradrenergic drugs on behavioral and neural
correlates of phasic noradrenergic responses (including the
P3) may critically depend on an individual’s natural baseline
level of noradrenergic activity (e.g., Coull 1994; Luksys et al.
2009). Therefore, we collected a measure of trait anxiety,
which strongly correlates with baseline noradrenergic activity
(Howells et al. 2012; Ressler and Nemeroff 2000), and exam-
ined if the level of trait anxiety interacted with the effect of
treatment.
Methods
Participants
Sixteen healthy young adults (10 women), aged 18–28 years
(average age 22.0 years±3.2 standard deviation (SD)), were
included in the study in return for 100€. Only participants with
a systolic blood pressure above 100 mmHg (average 126.6±
15.6 SD), a diastolic blood pressure above 60mmHg (average
69.3±7.1 SD), and a heart rate above 60 beats per minute
(average 75.4±10.9 SD) were included in the study. All par-
ticipants underwent a medical screening and were considered
to be in satisfactory health. The use of medication that could
interfere with propranolol was stopped the day before. Partic-
ipants received an oral dose of 80 mg propranolol or placebo
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in a randomized, double-blind, counterbalanced crossover de-
sign. Propranolol and placebo were administered to each par-
ticipant on consecutive days (24 h in between administrations)
with both sessions at the same time of day. EEG was recorded
in both sessions during the performance of the oddball and
flanker task (described in detail below). The data from one
additional participant could not be collected because of severe
side effects of propranolol (de Rover et al. 2010), and the data
from one other additional participant was excluded because he
did not complete the tasks. The data from 16 participants were
analyzed. The study was approved by the medical ethics com-
mittee of the Leiden University Medical Center and was con-
ducted according to the Declaration of Helsinki. Informed
consent was obtained from all participants before their inclu-
sion in the study.
Procedure
Participants were instructed to abstain from caffeine, nico-
tine, alcohol, and other psychoactive substances from 15 h
before the start of the first session until the end of the sec-
ond session (the next day). After checking if blood pres-
sures and heart rate were still meeting the inclusion criteria,
participants received a microcrystalline cellulose-filled
capsule with either propranolol or placebo (t=0). Propran-
olol has well-established antihypertensive properties; there-
fore, blood pressure and heart rate were monitored for par-
ticipants’ safety. Measurements were taken at t=0, t=60, t=
90, t=100, t=115, t=130, t=145, and t=240. Between t=
100 and t=145, participants performed the three tasks re-
ported here in fixed order (Fig. 1). Given the slow pharma-
cokinetics of orally administered propranolol (Tmax=1–2 h,
T1/2=3–6 h), it is unlikely that any differences in results
between tasks were due to this fixed order. After comple-
tion of the tasks, the participants were debriefed and paid.
At t=240, participants were reevaluated and sent home if
blood pressure and heart rate were (near) normal.
Tasks and questionnaire
Participants first performed a visual and an auditory oddball
task, in fixed order. On each trial of the visual oddball task, a
black cross or circle (1.1×1.1°) was presented for 250 ms on a
light grey background. Participants were instructed to make
speeded key press responses with the dominant hand to target
stimuli (circles, 20% of the trials) but not to non-target stimuli
(crosses, 80 % of the trials). On each trial of the auditory
oddball task, a 150-ms tone (75 dB) was presented. Partici-
pants were instructed to fixate on a centrally presented fixation
cross and to make speeded key press responses with the dom-
inant hand to target tones (2000-Hz tones, 20 % of the trials)
but not to non-target tones (1000-Hz tones, 80 % of the trials).
In both tasks, the time interval between the onsets of two
successive stimuli was 2.5 s. Each task consisted of 150 ex-
perimental trials: 30 target trials and 120 non-target trials. Two
participants were excluded from the analysis of the auditory
oddball task data because of technical problems with the EEG
recording.
Next, participants performed a flanker task. Stimuli were
presented in white against a dark grey background on a com-
puter screen placed at a distance of 92 cm from the participant.
Each stimulus array subtended a visual angle of 5.5×0.6° and
consisted of five horizontally arranged letters displayed in
Arial font: HHHHH, SSSSS, HHSHH, or SSHSS. The partic-
ipants were instructed to respond Bas quickly and accurately as
possible^ to the central target letter and to try to ignore the four
flankers. The H was mapped to the left and the S to the right
response key. A distinction was made between congruent (i.e.,
target letter and flankers associated with the same response;
e.g., HHHHH) and incongruent (i.e., target letter and flankers
associated with different responses; e.g., HHSHH) stimulus
arrays. Each trial started with a 500-ms fixation cross, follow-
ed by the presentation of the stimulus array for 100 ms and a
blank screen until the response was registered. The response
was followed by another 500-ms blank screen, after which the
next trial started. Each participant completed six blocks of 80
trials each. Each block contained 20 trials with each of the four
possible stimulus arrays. Presentation order of the stimulus
arrays was randomized. After each block, the participants re-
ceived verbal feedback encouraging them to speed up or slow
down their responding, with the aim of maintaining accuracy
between 80 and 85 % correct. One participant was excluded
from the analysis of the flanker task data because of technical
problems with the EEG recording.
In a separate session, the participants filled out the 20-item
trait scale of the State-Trait Anxiety Inventory for Adults
(STAI; Spielberger et al. 1983), a standard anxiety question-
naire that measures trait anxiety on a 4-point scale.
Fig. 1 Timeline of the experiment. P view passive viewing task (de Rover et al. 2012), Vis oddball visual oddball task, Aud oddball auditory oddball
task, Flanker Flanker task, Wash out wash out period, to allow the heart rate to return to (approximately) baseline
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EEG recording and analyses
We recorded EEG from 31 Ag/AgCl scalp electrodes (Fp1,
AFz, Fz, F3, F7, FCz, FC3, FT7, Cz, C3, T7, CPz, CP3, TP7,
Pz, P3, P7, POz, O1, O2, P8, P4, TP8, CP4, T8, C4, FT8,
FC4, F8, F4, Fp2) and from the left and right mastoids. We
measured the horizontal and vertical electro-oculogram
(EOG) using bipolar recordings from electrodes placed ap-
proximately 1 cm lateral of the outer canthi of the two eyes
and from electrodes placed approximately 1 cm above and
below the participant’s right eye.
The EEG signal was pre-amplified at the electrode to im-
prove the signal-to-noise ratio and amplified with a gain of
16× by a BioSemi ActiveTwo system (BioSemi B.V., Amster-
dam). The data were digitized at 24-bit resolution with a sam-
pling rate of 512 Hz using a low-pass fifth-order sinc filter
with a half-power cutoff of 102.4 Hz. Each active electrode
was measured online with respect to a common mode sense
(CMS) active electrode producing a monopolar (non-
differential) channel and was referenced offline to the average
of the left and right mastoids. EEG and EOG were high-pass
filtered at 0.01 Hz. Ocular and eye blink artifacts were
corrected using the method of Gratton et al. (1983). Epochs
with other artifacts (spike artifacts (50 μV/2 ms) and slow
drifts (200 μV/200 ms)) were also discarded. We extracted
single-trial epochs for a period from 200 ms before to
600 ms after stimulus onset. Then, for each participant and
stimulus type, we averaged the EEG epochs to create
stimulus-locked (oddball tasks) and response-locked (flanker
task) event-related potentials (ERPs). The average signal dur-
ing the 200 ms pre-stimulus or pre-response baseline was
subtracted from each ERP. The P3 was defined as the peak
amplitude of the signal at electrode POz, where treatment
effects on P3 amplitude were most pronounced, in the time
window 150–550 ms. However, similar results were obtained
if the P3 was defined as the mean amplitude in the time win-
dow 230–400 ms. The Pe was defined as the peak amplitude
of the signal at electrode FCz in the time window 100–500 ms
(Overbeek et al. 2005). The ERN was defined as the mean
amplitude of the signal at electrode FCz in the time
window 0–150 ms. To examine the interaction between
treatment and trait anxiety, we included STAI trait score
(high or low, according to median split) as an additional
between-subject variable in all ERP analyses. The average
STAI trait (sum) score over all participants was 33.4±8.6
(SD) with a Cronbach’s alpha of 0.926. For the high-
anxiety group, the average STAI trait score was 40.1±6.8
(SD), and for the low-anxiety group, the average STAI trait
score was 26.8±3.2 (SD).
Results
Cardiovascular measurements
Heart rate was used as a marker to check for successful β-
receptor blockade by propranolol (Fig. 2). Heart rate was reg-
istered at baseline (t=0), just before the start of each task (pre-
test), and immediately after the end of each task (post-test).
For each of the three tasks, there was a significant decrease in
heart rate during the experiment (visual oddball task: F(2,
24)=67.4, p<0.001; auditory oddball task: F(2,18)=50.5,
p<0.001; flanker task: F(2,24)=135.2, p<0.001), which was
significantly larger for propranolol than for placebo treatment
(interaction time×treatment: visual oddball task: F(2,24)=
19.7, p<0.001; auditory oddball task: F(2,18)=19.6,
p<0.001; flanker task: F(2,24)=21.6, p<0.001). Subsequent
pairwise comparisons showed that baseline heart rate did not
differ between propranolol and placebo treatment (visual odd-
ball task: t15=1.7, p=0.11; auditory oddball task: t13=1.3, p=
0.21; flanker task: t14=2.0, p=0.07), whereas heart rate was
significantly lower in the propranolol condition than the pla-
cebo condition at pre-test (visual oddball task: t14=2.9, p=
0.013; auditory oddball task: t10=4.5, p=0.001; flanker task:
t12=4.2, p=0.001) and at post-test measurements (visual odd-
ball task: t12=4.3, p=0.001; auditory oddball task: t11=4.6,
p=0.001; flanker task: t14=3.0, p=0.009).
Visual oddball task Auditory oddball task Flanker task
Fig. 2 Cardiovascular measurements for each of the three tasks. BL baseline (t=0), Pretest right before the start of each task, Posttest immediately after
the end of each task. Error bars indicate standard errors of the means
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ERP oddball tasks
ERP waveforms for the visual oddball task are shown in
Fig. 3. The P3 showed the typical main effect of trial type,
indicating larger P3s to target stimuli than to non-target stim-
uli, F(1,14)=95.5, p<0.001, but no main effect of treatment,
F(1,14)=0.3, p=0.58. However, as Fig. 4 shows, the main
effect of treatment on P3 amplitude was obscured by a cross-
over interaction with trait anxiety level, F(1,14)=7.2, p=
0.018. We investigated this interaction further using separate
ANOVAs for the two anxiety groups. In the low-anxiety
group (Fig. 4a), there was no reliable main effect of treatment,
F(1,7)=1.5, p=0.26, but note that propranolol treatment led to
numerically smaller P3s, especially to targets (placebo
16.5 μV, propranolol 14.4 μV). In contrast, in the high-
anxiety group (Fig. 4b), propranolol treatment led to signifi-
cantly larger P3s, as indicated by a main effect of treatment:
F(1,7)=10.0, p=0.016 (target P3s—placebo 9.8 μV, propran-
olol 11.7 μV).
ERP waveforms for the auditory oddball task are shown in
Fig. 5. The P3 showed the typical main effect of trial type,
indicating larger P3s to target stimuli than to non-target stim-
uli, F(1,12)=588.6, p<0.001, and, importantly, a main effect
of treatment, F(1,12)=5.3, p=0.040, indicating larger P3s fol-
lowing propranolol treatment (placebo 8.1 μV, propranolol
9.2 μV). For the auditory task, there was no significant inter-
action between treatment and trait anxiety levels, F(1,12)=
0.04, p=0.85 (Fig. 6).
ERP flanker task
ERPwaveforms for the flanker task are shown in Fig. 7. There
were no main effects of congruency or interactions between
treatment and congruency (all ps>0.4), so the waveforms
shown were collapsed across this factor. In the ERN analysis,
only the main effect of accuracy was significant, F(1,13)=
31.2, p<0.001, indicating greater negativity following errors.
There was no significant main effect of treatment, F(1,13)=
0.5, p=0.50, and no significant interaction between treatment
and accuracy, F(1,13)=0.1, p=0.71. Similar results were ob-
tained if the ERN was defined not as the mean amplitude but
as the maximum amplitude of the signal in the 0–150 ms post-
response window (main effect of treatment: F(1,13)=1.8, p=
0.20; interaction treatment×accuracy: F(1,13)=1.0, p=0.33).
Similarly, in the Pe analysis, only the main effect of accu-
racy was significant: F(1,13)=22.1, p<0.001, indicating a
larger positivity after errors. In both analyses, there was no
significant main effect of treatment (ERN: F(1,13)=0.5, p=
0.50; Pe: F(1,13)=0.1, p=0.76) and no significant interac-
tions. However, it is striking that the Pe amplitude on incorrect
trials was numerically larger after propranolol treatment (pla-
cebo 10.5 μV, propranolol 11.4 μV), just like the auditory
oddball P3 and the visual oddball P3 in the high-anxiety
group. To examine if participants showed similar treatment
effects on P3 and Pe amplitude, we correlated the treatment
effects on P3 amplitude to visual and auditory targets with the
treatment effect on the Pe to errors, but found no significant
correlations (visual: r=.11, p=.35; auditory: r=−.34, p=.13,
one-tailed), although it should be noted that the sample size
was rather small for effective correlation analysis. Visual in-
spection (Fig. 7, lower panel) and statistical analyses sug-
gested very similar results for the Pe at electrode POz, the
electrode used for the P3 analyses.
Behavior oddball tasks
The accuracy of responding was higher than 98 % in both
tasks under all conditions and not significantly affected by
treatment. Response times (RTs) on correct target trials were
not significantly affected by treatment in the visual oddball
task (propranolol, 311 ms; placebo, 327 ms; t15=1.7, p=.11)
and in the auditory oddball task (propranolol, 316 ms; place-
bo, 330 ms; t10=0.5, p=.61). Given that the effect of treatment
on P3 amplitude in the visual oddball task was obscured by a
crossover interaction with trait anxiety level, we examined
whether RTs in the visual oddball task showed a similar inter-
action effect. The treatment×trait anxiety level interaction was
indeed significant, F(1,14)=4.8, p=0.045. Correct RTs were
not significantly affected by propranolol in the low-anxiety
group (placebo, 303 ms; propranolol, 306 ms; t7=0.3,
p=.81). In contrast, correct RTs were significantly shortened
by propranolol in the high-anxiety group (placebo, 351 ms;
propranolol, 316 ms; t7=2.6, p=.04). This pattern more or less
mirrors that for P3 amplitude and indicates that larger P3 am-
plitudes tended to be associated with faster RTs, consistent
with previous research (e.g., Li et al. 2009). A similar modu-
lation by trait anxiety level was not found for RTs in the
auditory oddball task and flanker task, nor in other behavioral
analyses, indicating a unique correspondence between P3 and
RT results in the visual oddball task.
Fig. 3 Visual oddball task: grand average ERP waveforms associated
with targets and non-targets in the placebo (Plac) and propranolol (Prop)
condition. The shaded area indicates the time window used for P3 peak
detection
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Behavior flanker task
Trials with RTs>1000 ms were considered outliers and
discarded from analyses (0.4 % of the trials in the placebo
condition and 0.2 % of the trials in the propranolol condition
were discarded). RTs on correct trials were slower on incon-
gruent trials (362 ms) than on congruent trials (338 ms), F(1,
13)=45.7, p<.001, a typical flanker interference effect. There
was no significant main effect of treatment (propranolol,
347 ms; placebo, 353 ms), F(1,13)=0.2, p=.66, and no two-
way interaction, p=.55. Error rates showed a similar pattern:
Participants made more errors on incongruent trials (18.7 %)
than on congruent trials (9.7 %), F(1,13)=130.1, p<.001.
There was no significant main effect of treatment (proprano-
lol, 13.9 %; placebo, 14.5 %), F(1,13)=0.2, p=.66, and no
two-way interaction, p=0.84.
In a subsequent analysis, we computed post-error slowing
by comparing correct RTs following incongruent error trials
Fig. 5 Auditory oddball task: grand average ERP waveforms associated
with targets and non-targets in the placebo and propranolol condition. The
shaded area indicates the time window used for P3 peak detection
Fig. 4 Visual oddball task:
average ERP waveforms for a
low-anxiety participants and b
high-anxiety participants. The
shaded area indicates the time
window used for P3 peak
detection
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with those following incongruent correct trials. Participants
showed significant post-error slowing (369 vs. 346 ms), F(1,
13)=12.5, p=.004. Post-error slowing did not differ between
the propranolol and placebo conditions (both 23 ms).
Finally, we computed congruency sequence effects on cor-
rect RT and error rates. The congruency sequence effect refers
to the observation that congruency effects in conflict tasks
tend to be reduced following incongruent compared to con-
gruent trials (Duthoo et al. 2014; Egner 2007). Verguts and
Notebaert (2009) have proposed that the main component of
this effect reflects norepinephrine-mediated Hebbian learning,
presumably through actions at β-adrenergic receptors, which
play an important role in associative learning. To test this
proposal, we examined the effect of propranolol on the con-
gruency sequence effect.
Trials were included in the congruency sequence analyses
only if the response on the previous trial was correct and there is
no outlier. Participants did not show significant congruency
sequence effects in the RT data (previous×current trial type
interaction, p=.93) and error data (p=.21) (Fig. 8). Replicating
previous research, there was a significant three-way interaction
with response type (repetition vs. alternation) in the RT data,
F(1,13)=7.6, p=. 016, and error data, F(1,13)=6.3, p=.026,
indicating a robust congruency sequence effect for response-
repetition trials (i.e., trials on which the response was the same
as on the previous trial, e.g., HHSHH≫SSSSS) but not for
response-alternation trials (e.g., SSSSS≫SSHSS). This pattern
of results suggests that the presence of congruency sequence
effects reflects associative stimulus–response priming instead
of conflict-driven adaptations in cognitive control (Duthoo
et al. 2014). There were no reliable three-way interactions be-
tween treatment, previous and current trial type in the RT data,
F(1,13)=2.3, p=.16, and error data, F(1,13)=1.4, p=.25, and
no reliable four-way interactions in both the RT (p=.96) and
A. Low anxiety group
B. High anxiety group
Fig. 6 Auditory oddball task:
average ERP waveforms for a
low-anxiety participants and b
high-anxiety participants. The
shaded area indicates the time
window used for P3 peak
detection
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error data (p=.24). The RTcongruency sequence effect, defined
as the difference in flanker interference effect after incongruent
versus congruent trials, was 15 ms in the propranolol condition
and 3 ms in the placebo condition.
Discussion
There is a wealth of evidence suggesting an important role for
the noradrenergic system in the generation of the P3 (de Taeye
Fig. 8 Mean response times (RTs) and error rates for each combination
of current trial type and previous trial type, presented separately for
response change trials (left) and response repetition trials (right). CI—
previous trial type is congruent, current trial type is incongruent, CC—
previous trial type is congruent, current trial type is congruent, etc. Note
that a repetition of trial type (e.g., CC) can be associated with a change of
response (e.g., HHHHH≫SSSSS), and a change of trial type (e.g., IC) can
be associated with a response repetition (e.g., HHSHH≫SSSSS)
Fig. 7 Flanker task: grand
average response-locked ERP
waveforms at electrodes FCz
(upper panel) and POz (lower
panel) associated with correct and
incorrect responses in the placebo
and propranolol condition. The
shaded area indicates the time
window used for Pe peak
detection
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et al. 2014; Nieuwenhuis 2011; Nieuwenhuis et al. 2005). The
primary goal of this study was to extend our knowledge of the
neurochemical mechanisms underlying this relationship be-
tween noradrenergic system and P3. Previous pharmacologi-
cal studies have exclusively focused on agents that affect α2-
receptor signaling. Our study is the first to reportβ-adrenergic
effects on P3 amplitude. We found that P3s to auditory stimuli
in an oddball task were increased in amplitude following treat-
ment with propranolol, a centrally acting antagonist that
blocks noradrenergic signaling via post-synaptic β-receptors.
Propranolol also modulated the P3 to stimuli in the visual
oddball task, but the modulation went in opposite directions,
depending on the participants’ trait anxiety—a correlate of
baseline noradrenergic activity. In participants with lower trait
anxiety, propranolol resulted in a (non-significant) decrease in
P3 amplitudes. In participants with higher trait anxiety, pro-
pranolol significantly enhanced P3 amplitude. This pattern
was mirrored by a similar interaction in the RT data, indicating
a close correspondence between the brain and behavior. We
previously found a similar interaction between propranolol
and social anxiety for the late positive potential (de Rover
et al. 2012),1 an emotion-related sustained positivity that
shares some characteristics with the P3 (Hajcak et al. 2010).
It is difficult to explain these findings by referring to pro-
pranolol’s antagonist actions at post-synaptic beta receptors in
noradrenergic projection areas: if activation of these receptors
plays a major role in P3 generation, then it seems that block-
ade of these receptors should consistently decrease P3 ampli-
tude, which is in contrast to our findings. A better explanation
for our results, which also offers an account of the interaction
with trait anxiety, is that propranolol decreases tonic LC ac-
tivity through actions atβ2-receptors in the LC (Ampatzis and
Dermon 2010; Berridge and Waterhouse 2003). According to
this account, the effect of propranolol on P3 amplitude de-
pends on a subject’s baseline level of tonic LC activity, which
depends both on personality characteristics and task
characteristics.
Figure 9a illustrates our account of the results in the visual
oddball task. The figure shows the inverted U curve describ-
ing the relationship between tonic noradrenergic activity,
which can vary from low (inattentive states) to medium (alert
states) to high (stress and other high-arousal states) and phasic
noradrenergic activity, which is driven by task-relevant and
other motivationally significant stimuli (Aston-Jones and Co-
hen 2005). We assume that the high-anxiety group has a
higher baseline level of noradrenergic activity than the low-
anxiety group (Howells et al. 2012; Ressler and Nemeroff
2000). We also assume that in the visual oddball task, the
low- and high-anxiety groups are positioned on the tonic LC
axis such that propranolol shifts the low-anxiety group to a
lower point on the inverted U curve describing the strength of
phasic LC responses (which we assume underlies P3 genera-
tion; Nieuwenhuis et al. 2005). In contrast, propranolol shifts
the high-anxiety group to a higher point on the curve. This
account mirrors our explanation of the interactive effects of
propranolol and social anxiety on the late positive potential
(de Rover et al. 2012).
Figure 9b illustrates our account of the results in the audi-
tory oddball task. In order to explain the results, we need to
assume that participants were more aroused (i.e., had in-
creased tonic LC activity) while performing this task, either
because of the nature of the task or because the auditory odd-
ball task was consistently performed after the visual oddball
task. Unfortunately, our experiment was not designed to allow
a test of this assumption: We did not record autonomic ner-
vous system measures during task performance, and the dif-
ference in stimulation modality prevented a clean comparison
of baseline EEG frequency spectra. The assumed task-related
increase in arousal pushed both groups towards the right, such
that propranolol shifts both groups to a higher point on the
inverted U curve, thus resulting in a main effect of drug on P3
1 In this previous report (de Rover et al. 2012), the Liebowitz
Social Anxiety Scale (LSAS) was used to measure anxiety. In
the current study, we tested whether there was a three-way
interaction between treatment, P3 (or Pe or ERN) amplitude,
and LSAS score but did not find a significant interaction.
A. vis
B. aud
ual oddbal
itory oddb
l task
all task
Fig. 9 Schematic illustration of a potential mechanism underlying the
observed interaction between treatment and trait anxiety, for a the visual
oddball task and b the auditory oddball task. In this schematic drawing,
we assumed that the effects of task and trait anxiety are underadditive
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amplitude. We acknowledge that these accounts are highly
speculative—our data merely show a drug×trait anxiety
interaction for one task and a main effect of drug for the
other task. Future research, preferably with a larger sample
size and in a more heterogeneous population, should
attempt to replicate our results, while including autonomic
nervous system measures to empirically support assump-
tions about arousal.
Our pattern of results, a main effect of propranolol in
the auditory task but not the visual oddball task, resem-
bles the effects of the α2-receptor agonist clonidine on P3
amplitude in monkeys and humans. A review of this lit-
erature (Nieuwenhuis et al. 2005) shows that clonidine
fairly consistently decreases P3 amplitude in auditory
tasks while it does not affect P3 amplitude in visual tasks,
at least at the group level. Our study raises the question
whether these null effects at the group level are in fact an
average of opposing drug effects for different subgroups
of subjects, which differ systematically in trait anxiety or
other individual difference measures. The neural mecha-
nism may be similar to that proposed above for the effects
of propranolol, given that clonidine decreases tonic LC
activity through actions at α2-autoinhibition receptors in
the LC. Pineda and Swick (1992) suggested that these
modality-specific clonidine effects may reflect differences
in the number of receptors in visual and auditory cortical
areas. That is, noradrenergic fibers may preferentially in-
nervate regions involved in auditory analysis, causing
drug-induced changes in noradrenergic activity (and con-
sequent electrophysiological effects) to be more pro-
nounced in those areas. Although a similar account may
apply to the current results, this does not address the in-
teraction with trait anxiety in the visual oddball task.
More in general, it is also unclear how our findings can
be reconciled with Strange and Dolan (2007), who found
that propranolol decreased the large BOLD response elic-
ited by visual oddball targets, also in cortical areas known
to contribute significantly to the scalp-recorded P3.
Our new evidence for a relationship between the norad-
renergic system and the P3 could, in principle, inform our
understanding of the role of the noradrenergic system in
cognition (if we understood the cognitive process reflected
in the P3) or of the cognitive process underlying the P3 (if
we understood the link between noradrenergic activity and
cognition). However, there is very little consensus about
these topics, with prominent theories claiming a role for
the P3 process in updating of memory (Donchin and Coles
1988), evidence accumulation for perceptual decision
making (O’Connell et al. 2012; Verleger et al. 2005), and
post-decision temporal filtering (Nieuwenhuis et al. 2005).
This variety in theories is mirrored by prominent theories of
noradrenergic function, which link phasic noradrenergic
activity to arousal-based Hebbian learning (see Sara
2009), the accumulation of evidence for the occurrence of
unexpected events (Dayan and Yu 2006), and post-decision
temporal filtering (Aston-Jones and Cohen 2005). Until
more consensus is reached in one of these domains, our
findings mainly inform the neuromodulatory mechanism
underlying P3 generation and modulation by noradrenergic
agents.
Given the many parallels between the P3 and the Pe,
the second aim of our study was to examine whether
propranolol modulated not only the P3 but also the Pe.
Although the numerical effect of propranolol on Pe am-
plitude was of the same magnitude and in the same
direction as the propranolol effect on the auditory P3
(cf. Figs. 6 and 8), the effect on the Pe was far from
significant and did not correlate across subjects with the
propranolol effects on the P3. Although replication with
a large sample size is warranted, our finding suggests
that the generation of the Pe does not involve activation
of β-receptors. A previous study that examined the ef-
fect of the α2-receptor antagonist yohimbine also found
no effect on Pe amplitude (Riba et al. 2005). Future
attempts to unify theories of the P3 and Pe should take
into account these pharmacological findings.
Furthermore, our behavioral analyses showed that
propranolol did not modulate two types of conflict/error-
related adjustments. First, propranolol did not affect post-
error slowing, which in recent research has been tied to a
genetic marker of norepinephrine synthesis (Colzato et al.
2013). This finding is consistent with a recent study that
found no effect of propranolol on post-error slowing in
rats (Bari and Robbins 2013). Furthermore, propranolol
did not modulate congruency sequence effects, which in
our data reflect associative learning of stimulus–response
pairs (Egner 2007). This finding is potentially important,
because Verguts and Notebaert (2009) have hypothesized
that such associative learning effects in conflict tasks
reflect Hebbian learning, which is thought to occur
through actions at β-adrenergic receptors (see also Brown
et al. 2014). Altogether, the results in the flanker task
offered no evidence for a role of the β-adrenergic system
in error- and conflict-related processing.
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